NXERA Pharma operative highlights and consolidated results for the first quarter of 2025

Company highlights

Events after the period

• Neurocrine initiated a registration program of phase 3 of NBI-117568 as a potential treatment of schizophrenia in May 2025, which was supported by positive top line data from the phase 2 study and which achieved its primary endpoint for the once daily 20 mg dose (as reported in August 2024).

  • The phase 3 study is a global double-blind, placebo-controlled study to evaluate NBI-'568 in adults with a primary diagnosis of schizophrenia that have an acute exacerbation or a relapse of the symptoms.

  • The study is expected to register about 280 patients.

  • The primary endpoint of the study is a reduction in the basic line in the positive and negative syndrome scale (PANSSS).

  • The most important secondary endpoint is to improve the clinical global impression of the scale of severity (CGI-S).

• Executive dates

Financial highlights for the three -month period ended on March 31, 2025

• The turnover was 6,644 million JPY ($ 43.5 million*), an increase of 2,033 million jpy (USD 12.5 million) compared to the previous year. This increase was primarily due to the inclusion of the sales of Quviviq® after its introduction in the fourth quarter of 2024 and to the occurrence of a F&E milestone event in the current quarter compared to No -F & e mile stone event.

• The F&E expenditure amounted to 3.808 million jpy ($ 25.0 million), an increase of JPY by 645 million jpy ($ 3.7 million) compared to the previous year. This primarily reflects an increased investment in research and development and the effects of the weaker yen.

• SG & A expenditure amounted to JPY 3,701 million ($ 24.3 million), an increase of 51 million jpy (a decrease of $ 0.3 million) compared to the previous period. This increase was primarily due to incremental expenses for personnel to strengthen organizational skills, which were compensated for by lower sales costs due to targeted cost savings.

• The loss of operations in the previous year in the amount of JPY ($ 14.4 million) was 3,076 million (USD 20.7 million). This improvement in profitability reflects the combined effect of all movements explained above.

• The loss of income tax in the previous year in the amount of JPY $ 2,156 ($ 14.1 million) was lost in the previous year ($ 18.8 million). This improvement in profitability reflects the combined effect of all movements explained above.

• The net loss was JPY 760 million ($ 5.0 million) compared to a net loss of JPY 3,281 million (USD 22.1 million) in the previous year. This improvement in profitability reflects the combined effect of all movements explained above.

• Core operating loss ** achieved 625 million ($ 4.1 million) in the previous period compared to a core loss of 931 million JPY ($ 6.3 million).

• Cash and cash equivalent on March 31, 2025 amounted to 34,465 million jpy ($ 230.0 million) from the beginning of the year by JPY 2,197 million (24.3 million US dollars).

*Convenience conversion to US $ at the following prices: FJ 2025: 1us $ =152.57 JPY; Finished financial year 2024: 1us $ =148.40 JPY; 31 Damage 2025: 1us $ = 149.85 JPY; December 31, 2024: 1us $ = 156.83 Jpy
** Core operating profit / loss is an alternative performance measure that adapts to material costs and one -off costs to get insights into the recurring cash generation capacity of the core business.

-END-

About Nxera Pharma
NXERA PHARMA is a technological biopharma company to pursue new special medication in order to improve the life of patients with uncovered needs in Japan and globally.

In Japan, we have built up an agile business company for the new generation in Japan to develop and commercialize innovative medication, including several introduced products, in order to remedy this high value, large and growing market and those in the wider APAC region.

Therefore and with our unique NXWAVE ™ Discovery platform we cover an extensive pipeline from over 30 active programs from discovery to the late clinical phase internally and in cooperation with leading pharmaceutical and biotech companies. This pipeline potentially first and first -class candidates focuses on satisfying important needs in some of the fastest growing areas of medicine in the entire neurology/neuropsychiatry, metabolic diseases as well as immunology and inflammation.

Nxera employs approximately 400 talented people at important locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Exchange (ticker: 4565).

You can find more information at www.nxera.life
LinkedIn: @nxerapharma | X: @nxerapharma | YouTube: @nxerapharma

Inquiries:

NXera – media and investor relationships
Shinya Tsuzuki, VP, head of investor relationships
Shinichiro Nishishita, VP investor relationships, head of the obligation to regulate
Maya Bennison, communication manager
+81 (0) 3 5210 3399 | +44 (0) 1223 949390 |ir@nxera.life

Medistrava (for international media)
Mark Swallow, Frazer Hall, Erica Hollingsworth
+44 (0) 203 928 6900 | Nxera@istristrava.com

Predicted statements
This press release contains future -oriented statements, including statements about the discovery, development and marketing of products. Different risks can lead to the factual results of the NXERA PHARMA Group significantly distinguish from the expressed or implied statements of statements, including: side effects in clinical development programs; Not patent protection for inventions; Commercial restrictions due to patents belonging or controlled; Dependence on strategic alliance partners on the development and commercialization of products and services; Difficulties or delays in obtaining regulating permits for market products and services that arise from development efforts; the requirement for significant means to carry out research and development and expand the marketing activities; and product initiatives of competitors. As a result of these factors, potential investors are warned not to rely on future -oriented statements. We reject any intention or obligation to update or revise future statements, be it based on new information, future events or in any other way.

Attachment